TABLE 4

Number of subjects with thrombophlebitis and infusion site reactions after multiple-dose i.v. administration of placebo, vehicle, or posaconazole in part 2

Type of adverse eventNo. (%) of subjects with thrombophlebitis/infusion site reactions who received:Total (n = 18)
Placebo (n = 4)Posaconazole (mg)
0a (n = 9)50 (n = 5)
Thrombophlebitisb1 (25)1 (11)3 (60)5 (28)
Infusion site reactions0 (0)3 (33)4 (80)7 (39)
  • a Subjects received vehicle (cyclodextrin) only.

  • b In 4 of 5 subjects, thrombophlebitis was preceded by infusion site reactions that started on day 1 or 2.